New Research Shows Simufilam Suppresses Overactive mTOR
27 6월 2023 - 10:15PM
Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage
biotechnology company, today announced the publication of a new
paper in Frontiers in Aging, a peer-reviewed journal focused on
age-related scientific research. The new paper examined the effects
of simufilam on mTOR. Simufilam is Cassava Sciences’ novel, oral
drug candidate currently in Phase 3 clinical testing in patients
with mild-to-moderate Alzheimer's disease dementia.
“Today’s publication suggests a meaningful
impact of simufilam on overactive mTOR signaling,” said Lindsay
Burns, PhD, SVP Neuroscience at Cassava Sciences, and co-author of
the paper. “The data add to our understanding of simufilam’s
mechanism of action in Alzheimer's disease.”
The scientific literature shows overactive mTOR
plays a key role in aging, Alzheimer’s disease and other
conditions. When functioning normally, mTOR monitors cellular needs
and is activated by insulin. The research published today shows
mTOR is overactive in lymphocytes isolated from blood collected
from Alzheimer's patients versus healthy controls. After oral
administration of simufilam 100 mg twice daily to Alzheimer's
patients for 28 days, lymphocytes showed normalized mTOR activity
and restored mTOR sensitivity to insulin.
“Normalizing mTOR may have tantalizing potential
in Alzheimer’s disease and beyond,” said Remi Barbier, President
& CEO. “There is a wide body of research on this topic.”
An abstract of the research paper appeared
on-line June 23, 2023, ahead of print and is titled “Simufilam
Suppresses Overactive mTOR and Restores Its Sensitivity to Insulin
in Alzheimer’s Disease Patient Lymphocytes”. This paper is
open-access (free) under the terms of the Creative Commons
Attribution License. The full-text paper is expected to be
available on-line shortly.
About SimufilamSimufilam is
Cassava Sciences’ novel, oral drug candidate currently in Phase 3
clinical trials in patients with mild-to-moderate Alzheimer's
disease dementia. Simufilam binds tightly to and reverses an
altered conformation of the filamin A protein (FLNA) in Alzheimer’s
patients. Altered FLNA is critical to the toxicity of amyloid beta
(1-42). Simufilam is wholly owned by Cassava Sciences, without
royalty or payment obligation to any third party.
About Cassava Sciences,
Inc.Cassava Sciences is a clinical-stage biotechnology
company based in Austin, Texas. Our mission is to detect and treat
neurodegenerative diseases, such as Alzheimer’s disease. Our novel
science is based on stabilizing—but not removing—a critical protein
in the brain. Our product candidates have not been approved by any
regulatory authority, and their safety, efficacy or other desirable
attributes have not been established. For more information, please
visit our website: https://www.CassavaSciences.com
For More Information Contact:Eric Schoen, Chief
Financial Officer(512) 501-2450ESchoen@CassavaSciences.com
Cautionary Note Regarding
Forward-Looking Statements: This news release contains
forward-looking statements, including statements made pursuant to
the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995, that may include but are not limited to:
published research regarding simufilam and the mTOR protein; the
potential benefit, impact or significance of simufilam on mTOR in
humans; potential benefits to normalizing mTOR in humans; the
design, scope, conduct or intended purpose of our Phase 3 program
of simufilam in patients with Alzheimer's disease; the safety or
expected effects of mTOR or simufilam in Alzheimer’s disease, if
any; any expected clinical results of Phase 3 studies; the
treatment of people with Alzheimer’s disease dementia; the safety
or efficacy of simufilam in people with Alzheimer’s disease
dementia; verbal commentaries made by our employees; and potential
benefits, if any, of the our product candidates. These statements
may be identified by words such as “may,” “anticipate,” “believe,”
“could,” “expect,” “forecast,” “intend,” “plan,” “possible,”
“potential,” and other words and terms of similar meaning.
Simufilam is our investigational product
candidate. It is not approved by any regulatory authority in any
jurisdiction and its safety, efficacy or other desirable attributes
have not been established in patients.
Drug development and commercialization involve a
high degree of risk, and only a small number of research and
development programs result in commercialization of a product.
Clinical results from our prior studies may not be indicative of
results of future or larger scale clinical trials and do not ensure
regulatory approval. You should not place undue reliance on these
statements or any scientific data we present or publish.
Such statements are based largely on our current
expectations and projections about future events. Such statements
speak only as of the date of this news release and are subject to a
number of risks, uncertainties and assumptions, including, but not
limited to, those risks relating to the ability to conduct or
complete clinical studies on expected timelines, to demonstrate the
specificity, safety, efficacy or potential health benefits of our
product candidates, any unanticipated impacts of inflation on our
business operations, and including those described in the section
entitled “Risk Factors” in our Annual Report on Form 10-K for the
year ended December 31, 2022, and future reports to be filed with
the SEC. The foregoing sets forth many, but not all, of the factors
that could cause actual results to differ from expectations in any
forward-looking statement. In light of these risks, uncertainties
and assumptions, the forward-looking statements and events
discussed in this news release are inherently uncertain and may not
occur, and actual results could differ materially and adversely
from those anticipated or implied in the forward-looking
statements. Accordingly, you should not rely upon forward-looking
statements as predictions of future events. Except as required by
law, we disclaim any intention or responsibility for updating or
revising any forward-looking statements contained in this news
release. For further information regarding these and other risks
related to our business, investors should consult our filings with
the SEC, which are available on the SEC's website at
www.sec.gov.
Cassava Sciences (NASDAQ:SAVA)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
Cassava Sciences (NASDAQ:SAVA)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024